Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update

Readout of topline result expected in March 2024 from UV1 randomized Phase II trial INITIUM in Ultimovacs’ lead indication, advanced malignant melanomaTopline result will report primary endpoint of...

Related Keywords

Madrid ,Spain ,Norway ,Oslo ,Norwegian ,Hans Vassg ,Joachim Midttun ,Drug Administration ,Euronext Oslo Stock Exchange ,Fast Track ,Carlos De Sousa ,Hazard Ratio ,Overall Survival ,Orphan Drug ,Norwegian Securities Trading ,Financial Manager ,Markets ,